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Subsequent to the publication of the above article, the authors have realized that errors were introduced into [Fig. 4](#f4-or-41-04-2601){ref-type="fig"} at the typesetting stage. Essentially, in [Fig. 4B](#f4-or-41-04-2601){ref-type="fig"}, the P-value should have read as "P=0.13" (not as 0.013), and in [Fig 4D](#f4-or-41-04-2601){ref-type="fig"}, the labels for OBP^−^ and OBP^+^ were set the wrong way around. The correct version of [Fig. 4](#f4-or-41-04-2601){ref-type="fig"}, as originally submitted, is shown opposite.

The Editor apologizes to the authors for introducing these errors into their figure, and to the readership for any inconvenience caused.

![OBP-801 inhibits ARMS tumor growth and improves survival *in vivo*. (A) Six mice xenografted with luciferase-positive Rh30 cells were treated with vehicle or OBP-801 (10 mg/kg) for 6 weeks, starting on day 3 after tumor injection. We measured tumor-derived bioluminescence starting 3 days after beginning the treatment. Scale bar, 3.0 cm (B and C) Effect of OBP-801 on tumor growth and body weight in nude mice with subcutaneous xenografted RMS tumors (Rh30). Points indicate the mean tumor volumes or body weights (n=4); bars, SD. (D) Kaplan-Meier survival curve of xenografted mice treated with vehicle or OBP-801.](OR-41-04-2601-g00){#f4-or-41-04-2601}
